



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Rapaflo™

Common Name: Silodosin

PDL Category: BPH

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Doxazosin	Preferred
Flomax®	Non-Preferred
Terazosin	Preferred

Summary

Indications and Usage: Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).¹

Mechanism of Action: Selective antagonist of post-synaptic alpha-1 adrenoceptors causing smooth muscle relaxation resulting in an improvement of urine flow and a reduction in BPH symptoms.¹

Dosage Forms: Capsules: 4mg and 8mg

Recommended Dosage: 8 mg capsules taken orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment [Creatinine Clearance (CCr) 30-50 mL/min].¹

Common Adverse Drug Reactions: Retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.¹

Contraindications: Patients with severe renal impairment [Creatinine Clearance (CCr) < 30 mL/min]. Patients with severe hepatic impairment (Child-Pugh score > 10). Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir).¹

Manufacturer: Watson Pharmaceuticals, Inc.

Analysis: Rapaflo™ is a selective alpha-1 adrenergic receptor antagonist indicated for the treatment of the signs and symptoms of BPH. In the studies used to gain FDA approval, Rapaflo™ was only compared to placebo. No evidence is available that show Rapaflo™ is more effective than other alpha₁ blockers or that it causes less hypotension. Preferred alternatives appear on the Preferred Drug List which are more cost effective and have less potential risk for drug interactions. Therefore, it is recommended that Rapaflo™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Rapaflo™ [package insert]. Corona, CA: Watson Pharmaceuticals, Inc; 2008.